NCT04736147View on ClinicalTrials.gov

A Study of JNJ-64300535 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions
Healthy
Interventions
BIOLOGICAL

JNJ-64300535

JNJ-64300535 injection will be administered intramuscularly.

Trial Locations (1)

2650

SGS Belgium NV, Edegem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04736147 - A Study of JNJ-64300535 in Healthy Participants | Biotech Hunter | Biotech Hunter